Use of brom ergocryptine in treating amenorrhea/galactorrhea

A. G. Shapiro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Seven women with amenorrhea and galactorrhea, and no evidence of pituitary adenoma, were treated with brom-ergocryptine for two to 24 weeks. All seven patients had the resumption of regular menses within eight weeks, but six patients required 24 weeks of therapy to completely cease lactating. Two of the five women attempting to conceive became pregnant. Four of the five nonpregnant patients had a total recurrence of their symptoms after discontinuing the drug. Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility.

Original languageEnglish
Pages (from-to)720-721+724
JournalSouthern Medical Journal
Volume70
Issue number6
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Galactorrhea
Amenorrhea
Menstruation
Pituitary Neoplasms
Menstrual Cycle
Prolactin
Fertility
Recurrence
Pharmaceutical Preparations
ergocryptine
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of brom ergocryptine in treating amenorrhea/galactorrhea. / Shapiro, A. G.

In: Southern Medical Journal, Vol. 70, No. 6, 01.12.1977, p. 720-721+724.

Research output: Contribution to journalArticle

Shapiro, AG 1977, 'Use of brom ergocryptine in treating amenorrhea/galactorrhea', Southern Medical Journal, vol. 70, no. 6, pp. 720-721+724.
Shapiro, A. G. / Use of brom ergocryptine in treating amenorrhea/galactorrhea. In: Southern Medical Journal. 1977 ; Vol. 70, No. 6. pp. 720-721+724.
@article{a241c30e84cf4fee82ce8b3229184d35,
title = "Use of brom ergocryptine in treating amenorrhea/galactorrhea",
abstract = "Seven women with amenorrhea and galactorrhea, and no evidence of pituitary adenoma, were treated with brom-ergocryptine for two to 24 weeks. All seven patients had the resumption of regular menses within eight weeks, but six patients required 24 weeks of therapy to completely cease lactating. Two of the five women attempting to conceive became pregnant. Four of the five nonpregnant patients had a total recurrence of their symptoms after discontinuing the drug. Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility.",
author = "Shapiro, {A. G.}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "70",
pages = "720--721+724",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Use of brom ergocryptine in treating amenorrhea/galactorrhea

AU - Shapiro, A. G.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Seven women with amenorrhea and galactorrhea, and no evidence of pituitary adenoma, were treated with brom-ergocryptine for two to 24 weeks. All seven patients had the resumption of regular menses within eight weeks, but six patients required 24 weeks of therapy to completely cease lactating. Two of the five women attempting to conceive became pregnant. Four of the five nonpregnant patients had a total recurrence of their symptoms after discontinuing the drug. Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility.

AB - Seven women with amenorrhea and galactorrhea, and no evidence of pituitary adenoma, were treated with brom-ergocryptine for two to 24 weeks. All seven patients had the resumption of regular menses within eight weeks, but six patients required 24 weeks of therapy to completely cease lactating. Two of the five women attempting to conceive became pregnant. Four of the five nonpregnant patients had a total recurrence of their symptoms after discontinuing the drug. Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility.

UR - http://www.scopus.com/inward/record.url?scp=0017642633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017642633&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 720-721+724

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 6

ER -